← Back

Wire · opportunities

Finding drug targets in the tissue context with spatial biology

Published

17 August 2026

Topic

opportunities

Sectors

Biotech

Source

Read at drugdiscoverynews.com

Verified

Fusion42 · 17 August 2026 · Fusion42 review

Spatial biology enhances drug target discovery by preserving tissue context, enabling identification of both cell-type-specific and location-dependent targets that bulk and single-cell sequencing alone cannot reveal.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.

◆ The Wire takeaway

Biotech founders using drug discovery need to integrate spatial data to refine and validate targets beyond single-cell approaches. Your next screening pipeline should layer spatial biology onto genetics to avoid missing location-specific therapeutic targets.

Related on Wire

Topics

Biotechspatial-biologydrug-discoverysingle-cell-sequencingtherapeutic-targetsdisease-mapping